Fi­bro­Gen eyes re­bound path with Ph1 ADC da­ta for prostate can­cer drug

Af­ter a se­ries of clin­i­cal dis­ap­point­ments, Fi­bro­Gen could be on the come­back trail with promis­ing ear­ly da­ta from a CD46-tar­get­ing an­ti­body-drug con­ju­gate de­vel­oped by part­ner …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER